Amneal Pharmaceuticals price target raised to $6 from $5 at Barclays

Barclays raised the firm’s price target on Amneal Pharmaceuticals to $6 from $5 and keeps an Overweight rating on the shares. The company’s efforts over the past couple of years to transform its portfolio have started to bear fruit as Q3 mimicked Q2 with strength across complex generics, biosimilars and specialty, the analyst tells investors in a research note.